Table 2 Treatment related characteristics
N | IACRT group | SCRT group | P value |
|---|---|---|---|
Overall treatment time for radiation therapy (month) | 46.5 (range,8–73) | 52 (range,2–94) | 0.090 |
Total radiation dose (Gy) | 60 (range, 14–70.2) | 69 (range, 6–70.2) | 0.013 |
Radiation dose for prophylactic cervical LN node area (Gy) | 40 (range, 20–41.4) | 40 (range, 6–40) | 0.65 |
RT field Ipsilateral cervical LN area Bilatera cervical LN area Only primary tumor | Ipsilateral: 17 (25.8%) Bilateral: 45 (68.2%) Primary tumor: 4 (6.0%) | Ipsilateral: 3 (16.6%) Bilateral: 14 (77.8%) Primary tumor: 1 (5.6%) | 0.59 |
Chemotherapy | CCDP+DOC: 61 (92.5%) CDDP+5FU: 1 (1.5%) CDDP+DOC+cetuximab:2 (3.0%) CDDP only: 1 (1.5%) CDDP+ cetuximab: 1 (1.5%) | TS-1: 9 (50%) UFT:2 (11.1%) DOC+5FU: 1 (5.6%) Cetuximab: 6 (33.3%) | NA |
Gastrostomy | 36 (54.5%) Gastric tub: 13 (19.7%) Ingestion/oral intake17 (25.8%) | 4 (22.2%) Gastric tub: 3 (16.7%) Ingestion/oral intake:11 (61.1%) | 0.005 |